Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.

Biotechnology

Sonnet BioTherapeutics

Sonnet BioTherapeutics' headquarters in Princeton, NJ, United States

Susan Dexter

John K. Cini

Stephen J. McAndrew

Kal Ghosh

Jason Bock

Hossein Borghaei

Nailesh Bhatt

Guido Cavaletti

Donald Griffith

Albert Dyrness

Raghu Rao

Robert Wenham

Lori McNeill

The Directors at Sonnet BioTherapeutics oversee strategic decision-making, guide research and development efforts, ensure regulatory compliance, and manage key partnerships to advance the company's proprietary FHAB™ technology in developing innovative targeted biologic drugs.

Directors

The Leadership Team at Sonnet BioTherapeutics is responsible for setting the strategic direction and vision of the company, guiding the development of innovative biologic drugs leveraging the FHAB™ technology. Comprising key executives from finance, science, medical, and technical backgrounds, the team collaborates to drive research initiatives, oversee clinical development, ensure regulatory compliance, and foster partnerships to enhance the company's market position and therapeutic impact.

Leadership Team

The Advisory Team at Sonnet BioTherapeutics provides strategic guidance and expert insights to support the development and advancement of biologic drugs using the company's proprietary FHAB™ technology. Their collective expertise ensures that the company's innovative therapies achieve clinical and commercial success.

Sonnet BioTherapeutics

Org chart

Board & advisors

Teams

Directors

Leadership Team

Advisory Team

Offices

Sonnet BioTherapeutics

Org chart

Board & advisors

Teams

Directors

Leadership Team

Advisory Team

Offices

Related companies